Do Wall Street Analysts Like Incyte Corporation Stock?

Core Insights - Incyte Corporation (INCY) is focused on developing therapies for blood cancers, solid tumors, immune-mediated disorders, and dermatological diseases, with a market capitalization of approximately $19.6 billion [1] Stock Performance - Over the past 52 weeks, INCY stock has increased by 49%, outperforming the S&P 500 Index, which gained 14.4% during the same period [2] - Year-to-date, INCY stock remains slightly positive, while the broader index has increased by 1.4% [2] - The State Street SPDR S&P Biotech ETF (XBI) has risen by 40% over the past year and 2.2% year-to-date, slightly outperforming INCY in the shorter timeframe [3] Financial Results - Incyte's fourth-quarter 2025 results led to an 8.2% decline in shares, despite revenue growth exceeding Wall Street expectations [5] - Revenue surged by 27.8% year-over-year to $1.51 billion, surpassing analysts' estimate of $1.35 billion [5] - Adjusted EPS reached $1.80, which was below the $1.92 forecast but represented a 25.9% increase from the previous year [6] Future Outlook - Management projects total net product revenue for fiscal 2026 to be between $4.77 billion and $4.94 billion, with analysts forecasting diluted EPS of $6.66, indicating a 19.4% year-over-year growth [7] - Incyte has exceeded EPS estimates in three of the last four quarters, missing in only one [7] Analyst Sentiment - Wall Street maintains a "Moderate Buy" rating for INCY stock, with 12 analysts issuing a "Strong Buy," 13 recommending "Hold," and one assigning a "Strong Sell" [8] - Analyst sentiment has improved compared to three months ago, when only 11 analysts had a "Strong Buy" stance [10]